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Abstract
In medical research, a scenario often entertained is randomized controlled 22 factorial de-
sign with a binary outcome. By utilizing the concept of potential outcomes, Dasgupta et al.
(2015) proposed a randomization-based causal inference framework, allowing flexible and simul-
taneous estimations and inferences of the factorial effects. However, a fundamental challenge
that Dasgupta et al. (2015)’s proposed methodology faces is that the sampling variance of the
randomization-based factorial effect estimator is unidentifiable, rendering the corresponding
classic “Neymanian” variance estimator suffering from over-estimation. To address this issue,
for randomized controlled 22 factorial designs with binary outcomes, we derive the sharp lower
bound of the sampling variance of the factorial effect estimator, which leads to a new variance
estimator that sharpens the finite-population Neymanian causal inference. We demonstrate the
advantages of the new variance estimator through a series of simulation studies, and apply our
newly proposed methodology to two real-life datasets from randomized clinical trials, where we
gain new insights.
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tification; potential outcome.
∗Forthcoming in Statistical Methods in Medical Research.
†Address for correspondence: Jiannan Lu, One Microsoft Way, Redmond, Washington 98052-6399, U.S.A. Email:
jiannl@microsoft.com
1
ar
X
iv
:1
71
1.
04
43
2v
1 
 [s
tat
.M
E]
  1
3 N
ov
 20
17
1. INTRODUCTION
Since originally introduced to conduct and analyze agricultural experiments (Fisher 1935; Yates
1937), factorial designs have been widely applied in social, behavioral and biomedical sciences,
because of their capabilities to evaluate multiple treatment factors simultaneously. In particular,
over the past half-century, randomized controlled 22 factorial designs have become more well-
adopted in medical research, in which the research interest often lies in assessing the (main and
interactive) causal effects of two distinct binary treatment factors on a binary outcome. Among
the lengthy list of medical studies that are powered by 22 factorial designs (Chalmers et al. 1955;
Hennekens and Eberlein 1985; Eisenhauer et al. 1994; Rapola et al. 1997; Franke et al. 2000; Ayles
et al. 2008; Mhurchu et al. 2010; Greimel et al. 2011; Manson et al. 2012; James et al. 2013),
one of the most impactful examples is the landmark Physicians’ Health Study (Stampfer et al.
1985), in which over ten thousand patients were randomly assign to four experimental arms –
1. placebo aspirin and placebo β−carotene; 2. placebo aspirin and active β−carotene; 3. active
aspirin and placebo β−carotene; 4. active aspirin and active β−carotene. This study contained
multiple important end-points that were binary, e.g., cardiovascular mortality.
For traditional treatment-control studies (i.e., 21 factorial designs), a well-developed and pop-
ular methodology to conduct causal inference is the potential outcomes framework (Neyman 1923;
Rubin 1974), where we define causal effects as comparisons (difference, ratio, et al.) between the
treated and control potential outcomes, which are assumed to be fixed for each experimental unit.
Consequently, estimation and inference of causal effects solely depend on treatment assignment
randomization, which is often regarded as the gold standard for causal inference (Rubin 2008). As
a randomization-based methodology, the potential outcomes framework possesses several advan-
tages against other existing approaches, many of which are model-based. For example, it is fully
non-parametric and therefore more robust to model mis-specification, and better suited for finite
population analyses, which under certain circumstances are more appropriate as pointed by several
researchers (Miller 2006).
Realizing the salient feature of the potential outcomes framework, Dasgupta et al. (2015) for-
mally extended it to 2K factorial designs, by defining the factorial effects as linear contrasts of
potential outcomes under different treatment combinations, and proposing the corresponding esti-
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mation and inferential procedures. Dasgupta et al. (2015) argued that by utilizing the concept of
potential outcomes, the proposed randomization-based framework “results in better understanding
of” factorial effects, and “allows greater flexibility in statistical inference.” However it is worth
mentioning that, while “inherited” many desired properties of the potential outcomes framework,
inevitably it also inherited a fundamental issue – the sampling variance of the randomization-based
estimator for the factorial effects is unidentifiable, and therefore the corresponding classic “Ney-
manian” variance estimator suffers from the issue of over-estimation in general (see Section 6.5 of
Imbens and Rubin (2015) for a detailed discussion) – in fact, as pointed by Aronow et al. (2014),
it is generally impossible to unbiasedly estimate the sampling variance, because we simply cannot
directly infer the association between the potential outcomes. For treatment-control studies, this
problem has been extensively investigated and somewhat well-resolved, for binary (Robins 1988;
Ding and Dasgupta 2016) and more general outcomes (Aronow et al. 2014). However, to our
best knowledge, similar discussions appear to be absent in the existing literature for 2K factorial
designs, which are of both theoretical and practical interests. Motivated by several real-life exam-
ples in medical research, in this paper we take a first step towards filling this important gap, by
sharpening randomized-based causal inference for 22 factorial designs with binary outcomes. To be
more specific, we derive the sharp (formally defined later) lower bound of the sampling variance
of the factorial effect estimator, and propose the corresponding “improved” Neymanian variance
estimator.
The paper proceeds as follows. In Section 2 we briefly review the randomization-based causal
inference framework for 22 factorial designs, focusing on binary outcomes. Section 3 presents the
bias (i.e., magnitude of over-estimation) of the classic Neymanian variance estimator, derives the
sharp lower bound of the bias, proposes the corresponding improved Neymanian variance estimator,
and illustrate our results through several numerical and visual examples. Sections 4 conducts a
series of simulation studies to highlight the performance of the improved variance estimator. Section
5 applied our newly proposed methodology to two real-life medical studies, where new insights are
gained. Section 6 discusses future directions and concludes. We relegate the technical details to
Appendices A and B.
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2. RANDOMIZATION-BASED CAUSAL INFERENCE FOR 22
FACTORIAL DESIGNS WITH BINARY OUTCOMES
2.1. 22 factorial designs
To review Neymanian causal inference for 22 factorial designs, we adapt materials by Dasgupta
et al. (2015) and Lu (2016a), and tailor them to the specific case with binary outcomes. In 22
factorial designs, there are two treatment factors (each with two-levels coded as -1 and 1) and 4
distinct treatment combinations zj (j = 1, . . . , 4). To define them, we rely on the model matrix
(Wu and Hamada 2009)
H =

h0 h1 h2 h3
1 −1 −1 1
1 −1 1 −1
1 1 −1 −1
1 1 1 1

.
The treatment combinations are z1 = (−1,−1), z2 = (−1, 1), z3 = (1,−1) and z4 = (1, 1), and
later we will use h1, h2 and h3 to define the factorial effects.
2.2. Randomization-based inference
By utilizing potential outcomes, Dasgupta et al. (2015) proposed a framework for randomization-
based causal inference for 2K factorial designs. For our purpose, we consider a 22 factorial design
with N ≥ 8 experimental units. Under the Stable Unit Treatment Value Assumption (Rubin 1980),
for i = 1, . . . , N, we define Yi(zj) as the potential outcome of unit i under treatment combination
zj , and let Yi = {Yi(z1), Yi(z2), Yi(z3), Yi(z4)}′. In this paper we only consider binary outcomes,
i.e., Yi(zj) ∈ {0, 1} for all i = 1, . . . , N and j = 1, . . . , 4.
To save space, we introduce two sets of notations. First, we let
Dk1,k2,k3,k4 =
N∑
i=1
4∏
j=1
1{Yi(zj)=kj} (k1, k2, k3, k4 ∈ {0, 1}),
Consequently, instead of specifying the potential outcomes (Y1, . . . ,YN ) entry by entry, we can
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equivalently characterize them using the “joint distribution” vector (D0000, D0001, . . . , D1110, D1111),
where the indices are ordered binary representations of zero to fifteen. Second, for all non-empty
sets {j1, . . . , js} ⊂ {1, . . . , 4}, we let
Nj1,...,js =
N∑
i=1
1{Yi(zj1 )=1,...,Yi(zjs )=1}.
Therefore, for j = 1, . . . , 4, the average potential outcome for zj is
pj = N
−1
N∑
i=1
Yi(zj) = Nj/N,
and let p = (p1, p2, p3, p4)
′. Define the lth (individual and population) factorial effects as
τil = 2
−1h′lYi (i = 1, . . . , N); τ¯l = 2
−1h′lp, (1)
for l = 1, 2, 3, which correspond to the main effects of the first and second treatment factors, and
their interaction effect, respectively.
Having defined the treatment combinations, potential outcomes and factorial effects, next we
discuss the treatment assignment and observed data. Suppose for j = 1, . . . , 4, we randomly assign
nj (a pre-specified constant) units to treatment combination zj . Let
Wi(zj) =

1, if unit i is assigned to zj ,
0, otherwise;
(i = 1, . . . , N ; j = 1, . . . , 4)
be the treatment assignments, and
Y obsi =
4∑
j=1
Wi(zj)Yi(zj)
be the observed outcome for unit i, and
nobsj =
N∑
i=1
Wi(zj)Yi(zj) =
∑
i:Wi(zj)=1
Y obsi .
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Therefore, the average observed potential outcome for zj is pˆj = n
obs
j /nj , for all j = 1, . . . , 4.
Denote pˆ = (pˆ1, pˆ2, pˆ3, pˆ4)
′, and the randomization-based estimators for τ¯l is
ˆ¯τl = 2
−1h′lpˆ (l = 1, 2, 3), (2)
which are unbiased with respect to the randomization distribution.
Motivated by several relevant discussions in the existing literature (Freedman 2008; Lin 2013;
Dasgupta et al. 2015; Ding and Dasgupta 2016; Ding 2017), Lu (2016a,b) proved the consistency
and asymptotic Normality of the randomization-based estimator in (2), and derived its sampling
variance as
Var(ˆ¯τl) =
1
4
4∑
j=1
S2j /nj −
1
N
S2(τ¯l), (3)
where for j = 1, . . . , 4
S2j = (N − 1)−1
N∑
i=1
{Yi(zj)− pj}2 = N
N − 1pj(1− pj)
is the variance of potential outcomes for zj , and
S2(τ¯l) = (N − 1)−1
N∑
i=1
(τil − τ¯l)2
is the variance of the lth (individual) factorial effects in (1).
3. IMPROVING THE NEYMANIAN VARIANCE ESTIMATOR
3.1. Background
Given the sampling variance in (3), we estimate it by substituting S2j with its unbiased estimate
s2j = (nj − 1)−1
∑
i:Wi(zj)=1
{Y obsi − pˆj}2 =
nj
nj − 1 pˆj(1− pˆj),
and substituting S2(τ¯l) with its lower bound 0 (due to the fact that it is not identifiable, because
none of the individual factorial effects τil’s are observable). Consequently, we obtain the “classic
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Neymanian” variance estimator is
V̂arN(ˆ¯τl) =
1
4
4∑
j=1
s2j/nj =
1
4
4∑
j=1
pˆj(1− pˆj)
nj − 1 . (4)
This estimator over-estimates the true sampling variance on average by
E
{
V̂arN(ˆ¯τl)
}
−Var(ˆ¯τl) = S2(τ¯l)/N, (5)
unless strict additivity (Dasgupta et al. 2015) holds, i.e.,
τil = τi′l (∀i, i′ = 1, . . . , N),
which is unlikely to happen in real-life scenarios, especially for binary outcomes (LaVange et al.
2005; Rigdon and Hudgens 2015). We summarize and illustrate the above results by the following
example.
Example 1. Consider a hypothetical 22 factorial design with N = 16 units, whose potential
outcomes, factorial effects and summary statistics are shown in Table 1, from which we draw
several conclusions – first, the population-level factorial effects in (1) are -0.1563, -0.0313 and -
0.0313, respectively; second, the sampling variances of the randomization-based estimators in (2)
are 0.0425, 0.0493 and 0.0493, respectively; third, if we employ the classic Neymanian variance
estimator in (4), on average we will over-estimate the sampling variances by 52.5%, 31.6% and
31.6%, respectively.
3.2. Sharp lower bound of the sampling variance
As demonstrated in previous sections, the key to improve the classic Neymanian variance estimator
(4) is obtaining a non-zero and identifiable lower bound of S2(τ¯l). To achieve this goal, we adopt
the partial identification philosophy, commonly used in the existing literature to bound either the
randomization-based sampling variances of causal parameters (Aronow et al. 2014), or the causal
parameters themselves (Zhang and Rubin 2003; Fan and Park 2010; Lu et al. 2015).
We first present two lemmas, which play central roles in the proof of our main theorem.
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Table 1: Hypothetical potential outcomes, factorial effects and summary statistics for a 22 factorial design
with 16 experimental units.
Unit Potential outcomes Factorial Effects
(i) Yi(z1) Yi(z2) Yi(z3) Yi(z4) τi1 τi2 τi3
1 1 1 1 0 -0.5 -0.5 -0.5
2 0 0 1 1 1.0 0.0 0.0
3 1 1 0 0 -1.0 0.0 0.0
4 1 0 1 0 0.0 -1.0 0.0
5 0 1 0 0 -0.5 0.5 -0.5
6 1 0 0 1 0.0 0.0 1.0
7 0 1 0 0 -0.5 0.5 -0.5
8 1 1 0 1 -0.5 0.5 0.5
9 0 1 1 0 0.0 0.0 -1.0
10 0 0 1 1 1.0 0.0 0.0
11 1 1 0 0 -1.0 0.0 0.0
12 1 0 0 0 -0.5 -0.5 0.5
13 0 1 0 1 0.0 1.0 0.0
14 0 0 0 0 0.0 0.0 0.0
15 1 1 1 0 -0.5 -0.5 -0.5
16 1 0 1 1 0.5 -0.5 0.5
Mean p1 p2 p3 p4 τ¯1 τ¯2 τ¯3
= 0.5625 = 0.5625 = 0.4375 = 0.3750 = -0.1563 = -0.0313 = -0.0313
Variance S21 S
2
2 S
2
3 S
2
4 S
2(τ¯1) S
2(τ¯2) S
2(τ¯3)
= 0.2625 = 0.2625 = 0.2625 = 0.2500 = 0.3573 = 0.2490 = 0.2490
Lemma 1. Let hl = (h1l, h2l, h3l, h4l)
′ for all l = 1, 2, 3. Then
S2(τ¯l) =
1
4(N − 1)
 4∑
j=1
Nj +
∑
j 6=j′
hljhlj′Njj′
− N
N − 1 τ¯
2
l .
Lemma 2. For all l = 1, 2, 3, define
Jl− = {j : hlj = −1}, Jl+ = {j : hlj = 1}.
Then
4∑
j=1
Nj +
∑
j 6=j′
hljhlj′Njj′ ≥
∣∣∣∣∣∣
4∑
j=1
hljNl
∣∣∣∣∣∣ , (6)
and the equality in (6) holds if and only if
∑
j∈Jl+
Yi(zj)− 1 ≤
∑
j∈Jl−
Yi(zj) ≤
∑
j∈Jl+
Yi(zj) (i = 1, . . . , N) (7)
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or ∑
j∈Jl+
Yi(zj) ≤
∑
j∈Jl−
Yi(zj) ≤
∑
j∈Jl+
Yi(zj) + 1 (i = 1, . . . , N). (8)
We provide the proofs of Lemmas 1 and 2 in Appendix A. With the help of the lemmas, we
present an identifiable sharp lower bound of S2(τ¯l).
Theorem 1. The sharp lower bound for S2(τ¯l) is
S2LB(τ¯l) =
N
N − 1 max {|τ¯l|(1/2− |τ¯l|), 0} . (9)
The equality in (9) holds if and only if (7) or (8) holds.
By employing the inclusion-exclusion principle and Bonferroni’s inequality, we provide the proof
of Theorem 1 in Appendix A. The lower bound in Theorem 1 is sharp in the sense that it is
compatible with the marginal counts of the potential outcomes (N1, N2, N3, N4) (and consequently
τ¯l). To be more specific, for fixed values of (N1, N2, N3, N4), there exists a hypothetical set of
potential outcomes (Y ∗1 , . . . ,Y ∗N ), such that
N∑
i=1
Y ∗i (zj) = Nj (j = 1, . . . , 4); S
∗2(τ¯l) = S2LB(τ¯l).
Theorem 1 effectively generalizes the discussions regarding binary outcomes by Robins (1988)
and Ding and Dasgupta (2016), from treatment-control studies to 22 factorial designs. In particular,
the conditions in (7) and (8) echo the parallel results by Ding and Dasgupta (2016), and therefore
we name them the “generalized” monotonicity conditions on the potential outcomes. However,
intuitive and straightforward as it seems, proving Theorem 1 turns out to be a non-trivial task.
3.3. The “improved” Neymanian variance estimator
The sharp lower bound in (9) leads to the “improved” Neymanian variance estimator
V̂arIN(ˆ¯τl) =
1
4
4∑
j=1
pˆj(1− pˆj)
nj − 1︸ ︷︷ ︸
V̂arN(ˆ¯τl)
− 1
N − 1 max
{|ˆ¯τl|(1/2− |ˆ¯τl|), 0}︸ ︷︷ ︸
Sˆ2LB(τ¯l)/N
, (10)
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which is guaranteed to be smaller than the classic Neymanian variance estimator in (4) for any
observed data, because the correction term on the right hand side of (10) is always non-negative.
For example, for balanced designs (i.e., n1 = n2 = n3 = n4) with large sample sizes, the relative
estimated variance reduction is
γl =
Sˆ2LB(τ¯l)/N
V̂arN(ˆ¯τl)
≈ |ˆ¯τl|(1/2− |ˆ¯τl|)∑4
j=1 pˆj(1− pˆj)
.
We illustrate the above results by the following numerical example.
Example 2. Consider a balanced 22 factorial design with N = 400 experimental units, so that
(n1, n2, n3, n4) = (100, 100, 100, 100). For the purpose of visualizing the estimated variance reduc-
tion under various settings, we repeatedly draw
nobsj
iid.∼ bUnif(0, 100)c (j = 1, . . . , 4)
for 5000 times, and plot the corresponding γ1’s in Figure 1. We can draw several conclusions
from the results. First, for 13% of the times γ1 is smaller than 1%, corresponding to cases where
ˆ¯τl ≈ −0.5, 0 or 0.5. Second, for 13% of the times γ1 is larger than 10%. Third, the largest γ1
is approximately 20.5%, corresponding to the case where (nobs1 , n
obs
2 , n
obs
3 , n
obs
4 ) = (0, 0, 16, 14) and
ˆ¯τ1 = 0.15.
As pointed out by several researchers (Aronow et al. 2014; Ding and Dasgupta 2016), the prob-
abilistic consistency of the factorial effect estimator ˆ¯τl guarantees that the improved Neymanian
variance estimator still over-estimates the sampling variance on average, unless one of the general-
ized monotonicity conditions in (7)–(8) holds. Nevertheless, it does improve the classic Neymanian
variance estimator in (4), and more importantly, this improvement is the “best we can do” without
additional information. In the next section, we conduct simulation studies to demonstrate the finite-
sample properties of, and to compare the performances of, the classic and improved Neymanian
variance estimators.
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Figure 1: Visualization of the relative variance estimation reduction for ˆ¯τ1, through 5000 repeated
samplings of (nobs1 , n
obs
2 , n
obs
3 , n
obs
4 ) using the Uniform distribution.
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4. SIMULATION STUDIES
To save space, we focus on the first factorial effect τ¯1 and its randomization-based statistical infer-
ence. To mimic the empirical examples that we will re-analyze in the next section, we choose the
sample size N = 800. Moreover, to (at least to some extent) explore the complex dependence struc-
ture of the potential outcomes, we adopt the latent multivariate Normal model for the underlying
data generation mechanism is. To be more specific, let
ηi = {ηi(z1), ηi(z2), ηi(z3), ηi(z4)}′ iid.∼ N (µ,Σ) (i = 1, . . . , N),
and assume that for each i
Yi(zj) = 1{ηi(zj)≥0} (j = 1, . . . , 4).
We consider the following six cases:
µ =
Case 1︷ ︸︸ ︷
(−2,−2,−2,−2),
Case 2︷ ︸︸ ︷
(0, 0, 0, 0)︸ ︷︷ ︸
τ¯1≈0
,
Case 3︷ ︸︸ ︷
(0, 0, 0, 2),
Case 4︷ ︸︸ ︷
(−2,−2, 0,−2)︸ ︷︷ ︸
τ¯1≈0.25
,
Case 5︷ ︸︸ ︷
(−2,−2,−2, 2),
Case 6︷ ︸︸ ︷
(−2, 0, 0, 2)︸ ︷︷ ︸
τ¯1≈0.5
.
We choose the above values for µ, so that the corresponding factorial effects τ¯1 ≈ 0 (the approxi-
maition is due to finite-sample fluctuation) for Cases 1–2. Similarly, τ¯1 ≈ 0.25 for Cases 3 and 4,
and τ¯1 ≈ 0.5 for Cases 5 and 6. Therefore, we can examine the scenarios where the sharp lower
bound S2LB(τ¯l) in (10) are either small or large in magnitude. Moreover, we partially adopt the
simulation settings by Dasgupta et al. (2015) and let
Σ =

1 ρ ρ ρ
ρ 1 ρ ρ
ρ ρ 1 ρ
ρ ρ ρ 1
 (ρ = −1/3, 0, 1/2),
which corresponds to negatively correlated, independent and positively correlated potential out-
comes, respectively. The aforementioned data generation mechanism resulted eighteen “joint distri-
butions” of the potential outcomes (D0000, D0001, . . . , D1111), which we report in the third column of
Table 2. For each simulation case (i.e., row of Table 2), we adopt the following three-step procedure:
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1. Use (1) and (3) to calculate τ¯1, the sampling variance of its randomization-based estimator
and its lower bound, respectively, and report them in the fourth to sixth columns of Table 2;
2. Independently draw 10000 treatment assignments from a balanced 22 factorial design with
(n1, n2, n3, n4) = (200, 200, 200, 200);
3. For each observed data-set, use (2), (4) and (10) to calculate the point estimate of τ¯1, the
classic and improved Neymanian variance estimates respectively, based on which we construct
two 95% confidence intervals.
To examine the performances of the classic and improved Neymanian variance estimators in (4) and
(10), in the last six columns of Table 2, we report the relative (i.e., percentage wise) over-estimations
of the true sampling variance, the average lengths and the coverage rates of their corresponding
confidence intervals of the two estimators, respectively.
We can draw several conclusions from the results. First, because of the non-negative correction
term Sˆ2LB(τ¯l)/N, for all cases the improved Neymanian variance estimator (10) reduces the over-
estimation of the sampling variance, shortens the confidence intervals and achieves better coverage
rates without under-covering. For example, in Case 4 with ρ = 1/2, the improved Neymanian
variance estimator reduces the coverage rate from 0.974 to 0.956, achieving near nominal level.
Second, by comparing Case 1 with Case 2 (or 3 with 4, 5 with 6), we can see that for a fixed
τ¯l, although the absolute magnitude of the correction term is the same, the performance (i.e.,
reduction of percentage of over-estimation, average length and coverage rate) of the improved
Neymanian variance estimator might differ significantly, depending on the “marginal distributions”
of the potential outcomes (characterized by the mean parameter µ). Third, for a fixed marginal
distribution, the performance of the improved Neymanian variance estimator might also differ
significantly, depending on the dependence structure of the potential outcomes (characterized by
the association parameter ρ). Fourth, in certain scenarios, while the improved Neymanian variance
estimator only slightly shortens the confidence interval, it leads to a non-ignorable improvement
on coverage rates. For example, in Case 5 with ρ = 0, a less than 5% shorter confidence interval
reduces the coverage rate from 0.976 to 0.966.
To take into account alternative data generation mechanisms and thus provide a more compre-
hensive pircute, in Appendix B we conduct an additional series of simulation studies, where we focus
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on several discrete outcome distributions. The results largely agree with the above conclusions.
5. EMPIRICAL EXAMPLES
5.1. A study on smoking habits
In 2004, the University of Kansas Medical Center conducted a randomized controlled 22 factorial
design to study the smoking habits of African American light smokers, i.e., those “who smoke 10
or fewer cigarettes per day for at least six months prior to the study” (Ahluwalia et al. 2006). The
study focused on two treatment factors – nicotine gum consumption (2gm/day vs. placebo), and
counseling (health education vs. motivational interviewing). Among N = 755 participants, n1 =
189 were randomly assigned to z1 (placebo and motivational interviewing), n2 = 188 to z2 (placebo
and health education), n3 = 189 to z3 (nicotine gum and motivational interviewing), and n4 = 189
to z4 (nicotine gum and health education). The primary outcome of interest was abstinence from
smoking 26 weeks after enrollment, determined by whether salivary cotinine level was less than 20
ng/ml. Ahluwalia et al. (2006) reported that (nobs1 , n
obs
2 , n
obs
3 , n
obs
4 ) = (13, 29, 19, 34).
We re-analyze this data set in order to illustrate our proposed methodology. To save space
we only focus on τ¯2, the main effect of counseling. The observed data suggests that its point
estimate ˆ¯τ2 = −0.082, the 95% confidence intervals based on the classic and improved Neymanian
variance estimators are (-0.129, -0.035) and (-0.127, -0.037), respectively. While the results largely
corroborate Ahluwalia et al. (2006)’s analysis and conclusion, the improved variance estimator does
provide a narrower confidence interval – the variance estimate by the improved Neymanian variance
estimator is 92.1% of that by the classic Neymanian variance estimator.
5.2. A study on saphenous-vein coronary-artery bypass grafts
The Post Coronary Artery Bypass Graft trial is a randomized controlled 22 factorial design con-
ducted between March 1989 and August 1991, on patients who were “21 to 74 years of age, had
low-density lipoprotein (LDL) cholesterol levels of no more than 200 mg/deciliter, and had had at
least two saphenous-vein coronary bypass grafts placed 1 to 11 years before the start of the study”
(Campeau et al. 1997). The study concerned two treatment factors – LDL cholesterol level lowering
(aggressive, goal is 60–85 mg/deciliter vs. moderate), and low-dose anticoagulation (1mg warfarin
14
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vs. placebo). Among N = 1351 participants, n1 = 337 were randomly assigned to z1 (moderate
LDL lowering and placebo), n2 = 337 to z2 (moderate LDL lowering and warfarin), n3 = 339
to z3 (aggressive LDL lowering and placebo), and n4 = 337 to z4 (aggressive LDL lowering and
warfarin). For the purpose of illustration, we define the outcome of interest as the composite end
point (defined as death from cardiovascular or unknown causes, nonfatal myocardial infarction,
stroke, percutaneous transluminal coronary angioplasty, or coronary-artery bypass grafting) four
years after enrollment. Campeau et al. (1997) (in Table 5 and Figure 2, pp. 160) reported that
nobs1 + n
obs
2 = 103, n
obs
3 + n
obs
4 = 85, n
obs
2 + n
obs
4 = 89, n
obs
4 = 68,
which implies that (nobs1 , n
obs
2 , n
obs
3 , n
obs
4 ) = (82, 21, 17, 68).
We re-analyze the interactive effect τ¯3. The observed data suggests that ˆ¯τ3 = 0.166, and the
95% confidence intervals based on the classic and improved Neymanian variance estimators are
(0.130, 0.202) and (0.133, 0.200), respectively. Again, the improved Neymanian variance estimator
provides a narrower confidence interval, because its variance estimate is only 87.7% of that by
the classic Neymanian variance estimator. Moreover, the results suggest a statistically significant
interactive effect between LDL cholesterol lowering and low-dose anticoagulation treatments, which
appeared to be absent in Campeau et al. (1997)’s original paper.
6. CONCLUDING REMARKS
Motivated by several empirical examples in medical research, in this paper we studied Dasgupta
et al. (2015)’s randomization-based causal inference framework, under which factorial effects are
defined as linear contrasts of potential outcomes under different treatment combinations, and the
corresponding difference-in-means estimator’s only source of randomness is the treatment assign-
ment itself. However, as pointed out by Aronow et al. (2014), a long standing challenge faced by
such finite-population frameworks is estimating the true sampling variance of the randomization-
based estimator. In this paper, we solve this problem and therefore sharpen randomization-based
causal inference for 22 factorial designs with binary outcomes, which is not only of theoretical in-
terest, but also arguably the most common and important setting for medical research among all
factorial designs. To be more specific, we propose a new variance estimator improving the clas-
16
sic Neymanian variance estimator by Dasgupta et al. (2015). The key idea behind our proposed
methodology is obtaining the sharp lower bound of the variance of unit-level factorial effects, and
using a plug-in estimator for the lower bound. Through several numerical, simulated and empirical
examples, we demonstrated the advantages of our new variance estimator.
There are multiple future directions based on our current work. First, although more of theo-
retical interests, it is possible to extend our methodology to general 2K factorial designs, or even
more complex designs such as 3k or fractional factorial designs. Second, we can generalize our
existing results for binary outcomes to other scenarios (continuous, time to event, et al.). Third,
although this paper focuses on the “Neymanian” type analyses, the Bayesian counterpart of causal
inference for 22 factorial designs might be desirable. However, it is worth mentioning that, instead
of adopting model-based approaches (Simon and Freedman 1997), we seek to extend Rubin (1978)’s
and Ding and Dasgupta (2016)’s finite-population Bayesian causal inference framework to factorial
designs, which requires a full Bayesian model on the joint distribution of the potential outcomes
under all treatment combinations. However, this direction faces several challenges. For example,
characterizing the dependence structure in multivariate binary distributions can be extremely com-
plex, as pointed out by Cox (1972) and Dai et al. (2013). Fourth, it would be interesting to explore
the potential use of our proposed variance estimator for constructions of non-parametric tests in
factorial designs (Solari et al. 2009; Pesarin and Salmaso 2010). Fifth, it is possible to further
improve our variance estimator, by incorporating pre-treatment covariate information. All of the
above are our ongoing or future research projects.
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A. PROOFS OF LEMMAS, THEOREMS AND COROLLARIES
Proof of Lemma 1. The proof in large follows (Dasgupta et al. Dasgupta et al. 2015). By (1)
N∑
i=1
τ2il = 2
−2
N∑
i=1
(h′lYi)
2
= 2−2
N∑
i=1
 4∑
j=1
hljYi(zj)
2
= 2−2
N∑
i=1
 4∑
j=1
h2ljY
2
i (zj) +
∑
j 6=j′
hljhlj′Yi(zj)Yi(zj′)

= 2−2
 4∑
j=1
h2lj
N∑
i=1
Y 2i (zj) +
∑
j 6=j′
hljhlj′
N∑
i=1
Yi(zj)Yi(zj′)

= 2−2
 4∑
j=1
Nj +
∑
j 6=j′
hljhlj′Njj′
 .
By combining the above and the fact that
S2(τ¯l) = (N − 1)−1
(
N∑
i=1
τ2il −Nτ¯2l
)
,
the proof is complete.
Proof of Lemma 2. We only prove the case where l = 1 and hl = (−1,−1, 1, 1)′, because other
cases (l = 2, 3) are analogous. We break down (6) to two parts:
4∑
j=1
Nj +
∑
j 6=j′
h1jh1j′Njj′ ≥
4∑
j=1
h1jNl (11)
and
4∑
j=1
Nj +
∑
j 6=j′
h1jh1j′Njj′ ≥ −
4∑
j=1
h1jNl, (12)
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and prove them one by one. It is worth emphasizing that, for the equality in (6) to hold, we only
need the equality in either (11) or (12) to hold.
To prove (11), note that
h11 = h12 = −1, h13 = h14 = 1,
and therefore (11) is equivalent to
N13 +N14 +N23 +N24 ≤ N1 +N2 +N34 +N12.
We use the inclusion-exclusion principal to prove the above. First, it is obvious that
N1234 ≤ N12, (13)
and the equality holds if and only if the set
{i : Yi(z1) = Yi(z2) = 1; Yi(z3) = 0 or Yi(z4) = 0} = ∅,
or equivalently
{i : Yi(z1) + Yi(z2) = 2; Yi(z3) + Yi(z4) < 2} = ∅. (14)
Second, note that
N13 +N14 −N134 = #{i : Yi(z1) = Yi(z3) = 1}+ #{i : Yi(z1) = Yi(z4) = 1}
−#{i : Yi(z1) = Yi(z3) = Yi(z4) = 1}
= #{i : Yi(z1) = 1; Yi(z3) = 1 or Yi(z4) = 1}
≤ #{i : Yi(z1) = 1}
= N1. (15)
The equality in (15) holds if and only if
{i : Yi(z1) = 1; Yi(z3) + Yi(z4) = 0} = ∅. (16)
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Third, by the same argument we have
N23 +N24 −N234 ≤ N2, (17)
and the equality in (17) holds if and only if
{i : Yi(z2) = 1; Yi(z3) + Yi(z4) = 0} = ∅. (18)
Fourth, by applying the similar logic, we have
N134 +N234 −N1234 ≤ N34, (19)
and the equality in (19) holds if and only if
{i : Yi(z1) + Yi(z2) = 0; Yi(z3) + Yi(z4) = 2} = ∅. (20)
By combining (13), (15), (17) and (19), we have proved that (11) holds. Moreover, the equality in
(11) holds if and only if (13), (15), (17) and (19) hold simultaneously, i.e., the four conditions in
(14), (16), (18) and (20) are met simultaneously. We leave it to the readers to verify that this is
indeed equivalent to (7), i.e. for all j = 1, . . . , N,
Yi(z3) + Yi(z4)− 1 ≤ Yi(z1) + Yi(z2) ≤ Yi(z3) + Yi(z4).
The proof of (12) is symmetrical, because it is equivalent to
N13 +N14 +N23 +N24 ≤ N3 +N4 +N34 +N12.
In particular, the equality in (12) holds if and only if (8) holds (again we leave the verification to
the readers). The proof is complete.
Proof of Theorem 1. The proof directly follows from (1), and Lemma 1 and 2.
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B. ADDITIONAL SIMULATION STUDIES
We conduct an additional series of simulation studies to take into account data generation mech-
anisms different from those described in Section 4. In order to generate a “diverse” set of joint
distributions of the potential outcomes D = (D0000, D0001, . . . , D1111) while keeping the simulation
cases closer to our empirical examples, we let
λ1 = 30, λj
iid.∼ Unif(0, 1) (j = 2, . . . , 16); p = (λ1, . . . , λ16)′
/ 16∑
j=1
λj ,
and
D | p ∼ Multinomial(800,p).
The main rationale behind the above data generation mechanism is that, in many medical studies
the (potential) primary endpoint (e.g., mortality) is zero for most patients under any treatment
combination. Indeed, our setting guarantees that on average 66.7% of the experimental units have
Yi(zj) = 0 for all j = 1, . . . , 4.
We use the aforementioned data generation mechanism to produce 50 simulation cases. For each
simulation case, we follow the procedure described in Section 4, and (to make the article concise)
report only the coverage results in Figure 2. The results largely agree with the conclusions made in
Section 4, i.e., the improved Neymanian variance estimator in (10) always, and sometimes greatly,
mitigates the over-estimation issue of the classic Neymaninan variance estimator.
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Figure 2: Additional simulation results: The horizontal axis contains the indices of the simulation
cases, and the vertical shows the coverage rates for the 95% classic (red rounded dot) and improved
(black triangular dot) Neymanian intervals.
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